Droxidopa - Lundbeck A/S

Drug Profile

Droxidopa - Lundbeck A/S

Alternative Names: 3,4-Dihydroxyphenylserine; 3,4-threo-DOPS; Dops; L-DOPS; L-threo-dihydroxyphenylserine; L-threodops; Northera; Threo-dopaserine; Threo-DOPS

Latest Information Update: 05 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Chelsea Therapeutics; Lundbeck A/S; Sumitomo Dainippon Pharma
  • Class Amino acids; Antiparkinsonians; Catecholamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Orthostatic hypotension
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy; Dizziness; Intradialytic hypotension; Orthostatic hypotension
  • Discontinued Attention-deficit hyperactivity disorder; Chronic fatigue syndrome; Fibromyalgia

Most Recent Events

  • 17 Aug 2018 Lundbeck A/S initiates a phase II trial in Orthostatic hypotension in USA (PO) (NCT03567447)
  • 24 Jun 2018 Biomarkers information updated
  • 11 May 2015 No recent reports of development identified - Phase-II for Intradialytic hypotension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top